Indication: Tukysa, a kinase inhibitor

Tukysa is a kinase inhibitor recommended in combination with Trastuzumab and Capecitabine for treating adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases who received one or more prior anti-HER2-based regimens in the metastatic setting and in combination with Trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive […]